EPCAM and metastatic neoplasm: With combination B, if the metastatic disease was adenocarcinoma, the cells were usually seen as red immunostaining (BerEP4 immunoreactivity) [Figure 3c] amongst variable numbers of reactive mesothelial cells with brown nuclei (calretinin immunoreactivity).